Podcast

Lee-Kim on Fostering a Fulfilling Fellowship in Oncology

Author(s):

Dr. Lee-Kim discusses her path into treating pediatric patients with cancer, key lessons that can be learned during fellowship, and tips on managing finances and burnout during a pediatric oncology fellowship program.

Welcome to OncLive On Air®, I'm your host today, Jason Harris.

OncLive On Air® is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technologies to treatment advances to important regulatory decisions.

In today's episode, we had the pleasure of speaking with YoungNa J. Lee-Kim, MD, MEd, for the Advice From the Director series for Oncology Fellows.

Dr. Lee-Kim is director of the fellowship program in pediatric hematology/oncology at the Texas Children's Cancer and Hematology Centers and an associate professor of pediatrics at the Baylor College of Medicine.

In our exclusive interview, Dr. Lee-Kim discusses her path into treating pediatric patients with cancer, key lessons that can be learned during fellowship, and tips on managing finances and burnout during a pediatric oncology fellowship program.

Related Videos
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.